Literature DB >> 9028353

Alkaline sphingomyelinase activity is decreased in human colorectal carcinoma.

E Hertervig1, A Nilsson, L Nyberg, R D Duan.   

Abstract

BACKGROUND: The metabolism of sphingomyelin generates important signals regulating cell proliferation and apoptosis. Previous studies found that the administration of colon carcinoma carcinogen was associated with an accumulation of membrane sphingomyelin, and that dietary sphingomyelin inhibited promotion of experimental colon carcinoma in mice, indicating that the abnormal metabolism of sphingomyelin is linked to colon carcinoma development. However, the changes in sphingomyelinase (SMase) activity in colon carcinoma have not been directly studied. The authors identified, specifically in the intestine, a distinctive alkaline SMase that differs from the known acidic and neutral SMases. The functions and clinical implications of the enzyme are unknown. This study examined the changes in all three SMase activities in human colorectal carcinoma.
METHODS: Tissue samples were taken from colorectal carcinoma and normal mucosa from 18 patients. After homogenization, the activities of acidic, neutral, and alkaline SMase, as well as ceramidase and alkaline phosphatase, were determined. The enzyme activities in cancer tissue were compared with normal tissue from the same patients.
RESULTS: In the normal tissue, there is an activity gradient from the ascending colon to the rectum for neutral and alkaline SMases but not for acidic SMase. In colorectal carcinoma, alkaline SMase activity was preferentially decreased by 75%, whereas acidic and neutral SMase activity decreased by 30% and 50%, respectively. No changes could be found for either ceramidase or alkaline phosphatase activity.
CONCLUSIONS: Alkaline SMase activity preferentially decreases in human colorectal carcinoma, suggesting a regulatory role of the enzyme in colon mucosa cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028353

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

Review 1.  Clinical application of ceramide in cancer treatment.

Authors:  Kazuki Moro; Masayuki Nagahashi; Emmanuel Gabriel; Kazuaki Takabe; Toshifumi Wakai
Journal:  Breast Cancer       Date:  2019-04-08       Impact factor: 4.239

Review 2.  Evolving concepts in cancer therapy through targeting sphingolipid metabolism.

Authors:  Jean-Philip Truman; Mónica García-Barros; Lina M Obeid; Yusuf A Hannun
Journal:  Biochim Biophys Acta       Date:  2013-12-30

3.  Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study.

Authors:  Duska Separovic; Anthony F Shields; Philip A Philip; Jacek Bielawski; Alicja Bielawska; Jason S Pierce; Adi L Tarca
Journal:  Anticancer Res       Date:  2017-03       Impact factor: 2.480

Review 4.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 5.  Metabolic Regulation of Apoptosis in Cancer.

Authors:  K Matsuura; K Canfield; W Feng; M Kurokawa
Journal:  Int Rev Cell Mol Biol       Date:  2016-07-30       Impact factor: 6.813

6.  Expression of alkaline sphingomyelinase in yeast cells and anti-inflammatory effects of the expressed enzyme in a rat colitis model.

Authors:  David Andersson; Knut Kotarsky; Jun Wu; William Agace; Rui-Dong Duan
Journal:  Dig Dis Sci       Date:  2008-11-07       Impact factor: 3.199

7.  The enterocyte microvillus is a vesicle-generating organelle.

Authors:  Russell E McConnell; James N Higginbotham; David A Shifrin; David L Tabb; Robert J Coffey; Matthew J Tyska
Journal:  J Cell Biol       Date:  2009-06-29       Impact factor: 10.539

8.  VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation.

Authors:  I Soo; K L Madsen; Q Tejpar; B C Sydora; R Sherbaniuk; B Cinque; L Di Marzio; M Grazia Cifone; C Desimone; R N Fedorak
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

Review 9.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

10.  Role of neutral ceramidase in colon cancer.

Authors:  Mónica García-Barros; Nicolas Coant; Toshihiko Kawamori; Masayuki Wada; Ashley J Snider; Jean-Philip Truman; Bill X Wu; Hideki Furuya; Christopher J Clarke; Agnieszka B Bialkowska; Amr Ghaleb; Vincent W Yang; Lina M Obeid; Yusuf A Hannun
Journal:  FASEB J       Date:  2016-09-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.